Could a more selective treatment mean brighter days for people with PIK3CA-driven vascular malformations?

If you or someone you love has a PIK3CA-driven vascular malformation, such as lymphatic malformations (LMs), or PIK3CA-related overgrowth spectrum (PROS), consider this clinical research study.

Who Can Participate?

We are enrolling individuals with PIK3CA-driven vascular malformations globally.

Eligible participants must:

  • Have a diagnosis of a PIK3CA-driven vascular malformation, such as lymphatic malformation or PROS (includes syndromes such as Klippel-Trenaunay, CLOVES, FAVA, MCAP, and more)
  • NOT have another genetic driver that is known to cause your disease

Additional requirements will apply. If you are interested, a study doctor can discuss these further with you.

About the ReInspire Study

The ReInspire Study is evaluating an investigational study drug called RLY-2608 in individuals with PIK3CA-driven vascular malformations. PIK3CA-driven vascular malformations may include lymphatic malformations and PIK3CA-related overgrowth spectrum (PROS). PROS consists of syndromes such as Klippel-Trenaunay, CLOVES, FAVA, MCAP, and more. These types of malformations are caused by mutations or changes in the PIK3CA gene, which create a malfunctioning form of the protein PI3Kα. When mutated, PI3Kα can cause vascular malformations and overgrowths throughout the body, along with other symptoms.

The study aims to learn more about the safety and effectiveness of the study drug, RLY-2608, in the treatment of individuals with a PIK3CA-driven vascular malformation. RLY-2608 is taken orally and is designed to specifically hinder the mutated PI3Kα protein that can cause PIK3CA-driven vascular malformations. By selectively targeting the mutated proteins and limiting impact on the non-mutated proteins, the study drug aims to reduce side effects and provide more effective treatment over non-mutant-selective therapies.

Investigational study drugs have not yet been approved by the US Food and Drug Administration (FDA) or any other regulatory agency, such as the European Commission in the EU, and are not available outside of a clinical research study.

Find a participating site

Study Design

The ReInspire Study is made up of three parts. Participants will only be enrolled in one part.

Part 1

Part 1 will determine the dose(s) of RLY-2608 that provides the most benefit with the least side effects.

Part 2

Part 2 will continue to collect data on the safety and effectiveness of the recommended dose(s) found during Part 1.

Part 3

Part 3 will open after Parts 1 and 2 and will further confirm the treatment effect of the drug. The treatment effect will be confirmed based on how effective the study drug is in reducing the size of lesions as well as reducing any disease-related symptoms.

What Does Study Participation Involve?

To enter the study, you will first need to give your consent, or permission, by reviewing and signing an informed consent form. No matter what part of the ReInspire Study you are enrolled in, your participation will consist of three periods:

Screening

A study doctor will evaluate you to see if the study is a good match. During this period, you will have a single or multiple screening visits to complete the tests or procedures, such as a physical exam, routine labs, MRI, and others, to determine if you meet the requirements to participate.

Treatment

If the study is a good match for you and you agree to take part, you will begin taking the study drug and attend monthly study site visits. Your treatment period will last as long as you and your doctor determine it is in your best interest, or until the study ends. Participants will be shown how to use a dosing diary at home to keep track of assigned study treatment dosing.

Follow-up

If you stop taking the study drug, your study doctor will continue to monitor your health for a period of time.

What Are PIK3CA-Driven Vascular Malformations?

PIK3CA-driven vascular malformations may include lymphatic malformations and PIK3CA-related overgrowth spectrum (PROS). PROS consists of syndromes such as Klippel-Trenaunay, CLOVES, FAVA, MCAP, and more.

This clinical research study is designed to learn about a potential new treatment option for PIK3CA-driven vascular malformations. These types of malformations are caused by mutations or changes in the PIK3CA gene, which create a malfunctioning form of the protein PI3Kα. When mutated, PI3Kα can cause vascular malformations and overgrowths throughout the body, along with other symptoms. Although everyone has a unique experience, common symptoms include pain, swelling, infections, and impaired physical functioning, which can significantly impact a person’s quality of life.

Find a Participating Research Site

If you would like to contact an active research site, enter your zip code to find the participating site(s) nearest you.

Active site locations

Full List of Participating Sites by State

Arkansas

Arkansas Children's Hospital

Dr. Shelley Crary

1 Children's Way

Slot 123

Little Rock, AR 72202

D' Ann Pierce

501-364-4440

piercecarold@uams.edu

California

UCLA/Cedars Sinai Medical

Dr. Vivian Chang

10833 Le Conte Ave

12-335 MDCC

Los Angeles, CA 90095

Mikayla Henderson

310-825-6763

mmhenderson@mednet.ucla.edu

Ages Seen : 2+

Stanford University

Dr. Joyce Teng

700 Welch Road

Suite 301

Palo Alto, CA 94304

Ramrada Lekwuttikarn

650-313-8207

ramrada1@stanford.edu

Ages Seen : 2–30

University of California, San Francisco

Dr. Beth Winger

550 16th St

4th Floor, Mailcode 0434

San Francisco, CA 94158

Beth Winger

415-502-1994

beth.winger@ucsf.edu

Colorado

Ages Seen : 0–25

Children's Hospital of Colorado

Dr. Taizo Nakano

13123 East 16th Avenue

B115

Aurora, CO 80045

Taizo Nakano

720-777-6663

taizo.nakano@childrenscolorado.org

Georgia

Children's Healthcare of Atlanta

Dr. Michael White

1575 Northeast Expressway

E-370-A

Atlanta, GA 30329

Gabrielle Dean

404-785-8700

gabrielle.dean@choa.org

Massachusetts

Boston Children’s Hospital

Dr. Marilyn Liang

450 Brookline Drive

Shields Warren 4th Floor

Suite 461

Boston, MA 02115

Vascular Anomalies Center

617-355-5226

vascular@childrens.harvard.edu

Missouri

Ages Seen : All Ages

Washington University

Dr. Bryan Sisk

425 South Euclid Ave

MSC 8116-0043-10

St. Louis, MO 63110

Catie Knoerle

314-747-1828

pedshemonctrialreferral@wustl.edu

Ohio

Cincinnati Children's Hospital Medical Center

Dr. Adrienne Hammill

Dept of Hematology

3333 Burnet Ave

MLC 7015

Cincinnati, OH 45229

Sarah (Lexie) Price

513-803-0226

Sarah.Price@cchmc.org

Ages Seen : All Ages

Cleveland Clinic

Dr. Michael Kelly

9500 Euclid Ave.

R3

Cleveland, OH 44195

Bea Ferreira Alves

216-636-1926

ferreia2@ccf.org

Texas

Ages Seen : 0–23

Texas Children's Hospital

Dr. Ionela Iacobas

1102 Bates Avenue

Ste 1580

Houston, TX 77030

Gaylon Stevenson

832-824-1518

gnsteve1@texaschildrens.org

Wisconsin

University of Wisconsin-Madison

Dr. Beth Drolet

1 South Park St

7th Floor

Madison, WI 53715

Department of Dermatology

608-287-2622

info@clinicaltrials.wisc.edu

Don’t see a research site near you? Reach out to ClinicalTrials@relaytx.com to learn more about our upcoming locations. For more information about this study, visit ClinicalTrials.gov or email ClinicalTrials@relaytx.com.

What You Should Know About Clinical Research Studies

Clinical research studies, also called clinical trials, aim to answer specific questions about how medicines work in the volunteers who take them. You should feel fully informed about what to expect from your participation in a clinical research study.

Researchers use clinical research studies to:

  • Learn about the safety and effects of investigational medicines
  • Help find new ways of using certain medications
  • Identify new treatment options
  • Answer specific health questions

Participation in any clinical research study is your choice. The clinical research team will inform you of the potential risks and benefits of participation, as well as possible side effects. To make an informed decision, talk to your healthcare providers about any questions you may have.

All clinical research studies are:

  • Developed to protect the rights, safety, and well-being of participants
  • Conducted according to strict scientific and ethical principles
  • Reviewed and approved by an institutional review board (IRB) or ethics committee (EC)